Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness

Bibliography

• BUJA LM, MCALLISTER HA: Anatomic abnormalities and pathogenesis. In: Cardiovascular Medicine (2'd edn). Willerson JT, Cohn JN (Eds), Churchill Livingstone, Philadelphia, USA (2000):503–520.
   Google Scholar
• RUSSELL MW, HUSE DM, DROWNS S, HAMEL EC, HARTZ SC: Direct medical costs of coronary artery disease in the United States. Am. J. Cardiol (1998) 81:1110–1115.
   PubMed Web of Science ®Google Scholar
• AMERICAN HEART ASSOCIATION: Heart disease and stroke statistics. American Heart Association, Dallas, TX, USA (2002):40.
   Google Scholar
• EISENSTEIN EL, SHAW LK,ANSTROM KJ et al.: Assessing the clinical and economic burden of coronary artery disease: 1986–1998. Med. Care (2001) 39:824–835.
   Google Scholar
• SLOSS EM, WICKSTROM SL, MCCAFFREY DF et al: Direct medical costs attributable to acute myocardial infarction and ischaemic stroke in cohorts with atherosclerotic conditions.Circulation (2001) 106(Suppl. II):3746.
   Google Scholar
• DOBSON AJ, ALEXANDER HM, HELLER RF, MALCOLM JA, STEELE PL: Trends in ischaemic heart disease in the Hunter Region of New South Wales 1985-1989.Med. fAust. (1991) 155:599–608.
   PubMedGoogle Scholar
• HUNINK MGM, GOLDMAN L, TOSTESON ANA et al.: The recent decline in mortality form coronary heart disease, 1980-1990. JAMA (1997) 277:535–542.
   PubMedGoogle Scholar
• KIRCHHOFF M, DAVIDSEN M, BRONNUM-HANSEN H et al: Incidence of myocardial infarction in the Danish MONICA population 1982-1991. Inter J. Epidemiol (1999) 28:211–218.
   PubMedGoogle Scholar
• KOSTIS JB, WILSON AC, LACY CR et al.: Time trends in the occurrence and outcome of acute myocardial infarction and coronary heart disease between 1986 and 1996 (A New Jersey statewide study). Am.j Cardiol (2001) 88:837–841.
   PubMedGoogle Scholar
• DAVIDSEN M, BRONNUM-HANSEN H, JORGENSEN T et al.: Trends in incidence, case-fatality and recurrence of myocardial infarction in the Danish MONICApopulation 1982–1991.Eur. Epidemiol (2001) 17:1139–1145.
   Google Scholar
• MARQUES-VIDAL P, RUIDAVETS J-B,CAMBOU J-P, FERRIE. RES J: Incidence, recurrence, and case fatality rates for myocardial infarction in southwestern France, 1985 to 1993. Heart (2000) 84:171–175.
   Google Scholar
• MURRAY CJL, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• ••The Global Burden of Disease Study usedvarious data sources to estimate worldwide and regional cause-of-death patterns in 1990 for age-sex groups in eight regions of the world.
   Google Scholar
• THE WORLD HEALTH REPORT: Making a Difference. World Health Organization, Geneva (1999).
   Google Scholar
• YUSUF S, REDDY S, OUNPUU S, ANAND S: Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 104:2746–2753.
   Google Scholar
• ••The first of a two-part article whichprovides an overview of the global burden of atherothrombotic CVD. discusses the epidemiological transition, provides estimates of the burden of CVD with specific focus on the developing countries, summarises key information on risk factors for CVD, and describes overarching factors influencing variations in CVD by ethnicity and region and the influence ofurbanisation. describes the burden of CVD by specific region or ethnic group, the risk factors of importance, and possible strategies for prevention.
   Google Scholar
• BONOW RO, SMAHA LA, SMITH SC, MENSAH GA, LENFANT C: World Heart Day 2002. The international burden of cardiovascular disease: responding to the emerging global epidemic.Circulation (2002) 106:1602–1605.
   Google Scholar
• KELLY DT: Paul Dudley White International lecture. Our future society. A global challenge. Circulation (1997) 95:2459–2464.
   Google Scholar
• HAYDEN M, PIGNONE M, PHILLIPS C, MULROW C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. (2002) 136:161–172.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis of five randomised trials involving 50,000 patients demonstrating the efficacy of aspirin for the primary prevention of CHD.
   Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• ••A collaborative meta-analysis of 287 randomised trials involving 200,000 patients demonstrating the efficacy and safety of antiplatelet therapy for the prevention of MI, stroke, or CV death among a broad range of patients at high risk of atherothrombotic vascular events.
   Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• •A randomised trial of 19,000 patients demonstrating that clopidogrel is modestly superior to aspirin for the prevention of MI, stroke, or death among patients at high risk of symptomatic atherothrombotic vascular events.
   Google Scholar
• BHATT DL, HIRSCH AT, RINGLEB PA,HACKE W, TOPOL EJ: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE trial investigators. Am. Heart j (2000) 140:67–73.
   PubMed Web of Science ®Google Scholar
• BHATT DL, MARSO SP, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. Cardiol (2002) 90:625–628.
   PubMed Web of Science ®Google Scholar
• BHATT DL, CHEW DP, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation (2001) 103:363–368.
   PubMed Web of Science ®Google Scholar
• THE CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS TRIAL INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N. Engl. Med. (2001) 345:494–502.
   PubMed Web of Science ®Google Scholar
• ••A landmark, randomised trialdemonstrating the efficacy of adding clopidogrel to aspirin compared with aspirin alone for preventing seriousvascular events in patients with non-ST elevation ACS.
   Google Scholar
• JNEID H, BHATT DL, CORTI R, BADIMON JJ, FUSTER V, FRANCIS GS: Aspn and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study. Arch. Intern. Med. (2003) 163:1145–1153.
   PubMed Web of Science ®Google Scholar
• MEHTA SR, YUSUF S, PETERS RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527–533.
   PubMed Web of Science ®Google Scholar
• STEINHUBL SR BERGER PB, MANN JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JA/VIA (2002) 288:2411–2420.
   Google Scholar
• •A randomised trial demonstrating the efficacy and safety of long-term clopidogrel (1 year) in patients undergoing PCI. A loading dose of clopidogrel given at least3 h prior to the procedure did not significantly reduce events at 28 days but a per protocol subgroup analysis suggested that a longer dosing interval between the loading dose and percutaneous coronary events may reduce events.
   Google Scholar
• HANKEY GJ, SUDLOW CLM, DUNBABIN DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systemic review of the evidence from randomized trials.Stroke (2000) 31:1779–1784.
   Google Scholar
• •Meta-analysis of the effectiveness of clopidogrel compared with aspirin for the prevention of stroke and other serious vascular events among patients at high risk of symptomatic vascular events.
   Google Scholar
• MEDICAL ECONOMICS STAFF: Drug topics red book. Medical Economics, Montvale, NJ, USA (2000).
   Google Scholar
• GASPOZ JM, COXSON PG,GOLDMAN PA et al.: Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N. Engl. Med. (2002) 346:1800–1806.
   Google Scholar
• •An analysis of the cost-effectiveness of aspirin and clopidogrel for the secondary prevention of cardiovascular events in patients with coronary heart disease using a computer simulation of the US population (Coronary Heart Disease Policy Model). This analysis concludedthat aspirin is attractive from a cost-effectiveness perspective while the incremental cost-effectiveness of clopidogrel is currently unattractive unless its use is restricted to patients who are ineligible for aspirin.
   Google Scholar
• ANNEMANS L, LAMOTTE M, LEVY E, LENNE X: Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. Med. Economics (2003) 6:55–68.
   Google Scholar
• •A cost-effectiveness analysis of aspirin versus clopidogrel in the secondary prevention of vascular events utilising a Markov model and data from the CAPRIE trial. The authors highlight the threshold that defines cost-effectiveness in various countries.
   Google Scholar
• EDELSON JT, TOSTESON AN, SAX P: Cost-effectiveness of misoprostol for prophylaxis against non-steroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA (1990) 264:41–47.
   PubMedGoogle Scholar
• MANDELBLATT JS, FRYBACK DG, WEINSTEIN MC, RUSSELL LB, GOLD MR: Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. I Gen. Intern. Med. (1997) 12:551–558.
   PubMedGoogle Scholar
• •A summary of the recommendations of the Panel on Cost-Effectiveness in Health and Medicine.
   Google Scholar
• MARISSAL JP, SELKE B, LEBRUN T:Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics (2000) 18:185–200.
   PubMed Web of Science ®Google Scholar
• CHAMBERS M, HUTTON J, GLADMAN J: Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics (1999) 16:577–593.
   PubMed Web of Science ®Google Scholar
• GORELICK PB, BORN GVR, D'AGOSTINO RB, HANLEY DF Jr, MOYE L, PEPINE CJ: Therapeutic benefit: Aspirin revisited in light of the introduction of clopidogrel. Stroke (1999) 30:1716–1721.
   PubMed Web of Science ®Google Scholar
• ANNEMANS L, LINDGREN P, FREI A, GABRIEL S, SPIESSER J: Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis. European Socieh, of Cardiology Annual Scientific Meeting. Vienna, Austria (2003) (Abstract P1302).
   Google Scholar
• ANNEMANS L, LINDGREN P, FREI A, GABRIEL S, SPIESSER J: Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions (PCI): a five European countries analysis. European Socieh, of Cardiology Annual Scientific Meeting. Vienna, Austria (2003) (Abstract P1300).
   Google Scholar
• LAMY A, CHROLAVICIUS S, GAFNI A et al.: The cost-effectiveness of the use of clopidogrel in acute coronary syndromes based upon the CURE study.Circulation (2002) 106(Suppl. II):3721.
   Google Scholar
• MEHTA SR, WEINTRAUB WS, JONSSON B et al.: Incremental cost-effectiveness of early and long term clopidogrel in patients undergoing PCI in the CURE trial: The PCI-CURE Economic Analysis. 52'd Annual Scientific Sessions of the American College of Cardiology Chicago, USA (2003) (Abstract 1171–112).
   Google Scholar
• FRANZOSI MG, FOR THE GISSI INVESTIGATORS: Ten year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italian° per lo Studio della Sopravvivenza nell'Infarto-1 Study. Circulation (1998) 98:2659–2665.
   PubMedGoogle Scholar
• LEVY E, GABRIEL S, CARITA P, DINET J: An economic evaluation of clopidogrel in secondary prevention of ischaemic events: High risk populations. Value Health (2002) 5:477-478 (PCV1).
   Google Scholar
• SARASIN FP, GASPOZ JM,BOUNAMEUAX H: Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischaemic attack. Arch. Intern. Med. (2000) 160:2773–2778.
   PubMedGoogle Scholar
• LINDGREN P, JONSSON B: Modelling the cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Sweden. 52'd Annual Scientific Sessions of the American College of Cardiology Chicago, USA (2003) (Abstract 885–2).
   Google Scholar
• VAN HOUT B: Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke and peripheral arterial disease in the Netherlands. ISPOR Congress, Barcelona, Spain (2003).
   Google Scholar
• DE LEMOS JA, MCGUIRE DK: Aspirin,clopidogrel, or both for secondary prevention of coronary disease. N Engl. Med. (2003) 348:561.
   Google Scholar
• POSTMA MJ, HEIJNEN ML,BEUTELS P et al: Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost-effectiveness analysis. Ned. Tijdschr. Ceneeskd (2002) 146:855–889.
   PubMedGoogle Scholar
• YOUNG M, PLOSKER GL: Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics (2001) 19:1227–1259.
   PubMed Web of Science ®Google Scholar
• BERTHELOT JM, WILL BP, EVANS WK et al.: Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.aNatl. Cancer Inst. (2000) 92:1321–1329.
   PubMed Web of Science ®Google Scholar
• MARK DB, HARRINGTON RA, LINCOFF AM et al.: Cost-effectiveness of platelet Glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation (2000) 101:366–371.
   PubMed Web of Science ®Google Scholar
• GARBER AM, PHELPS CE: Economic foundations of cost-effectiveness analysis. Heath Economics (1997) 16:1–31.
   PubMed Web of Science ®Google Scholar
• WHO COMMISSION ON MACROECONOMICS AND HEALTH: Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. WHO, Geneva, Switzerland (2001).
   Google Scholar
• MURRAY CJ, LAUER JA,HUTUBESSY RCW et al.: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global andregional analysis on reduction of cardiovascular risk. Lancet (2003) 361:717–725.
   Google Scholar
• MULS E, VAN GANSE E, CLOSON MC: Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis (1998)137(Suppl.): S111–S116.
   Google Scholar
• BROWN AID, GARBER AM: A concise review of the cost-effectiveness of coronary heart disease prevention. Med. Clin. N Am. (2000) 84:279–297.
   PubMedGoogle Scholar
• •An informative review and comparison of the cost-effectiveness of lifestyle modification, treatment of hypertension and management of hyperlipidaemia.
   Google Scholar
• CARO JJ, MIGLIACCIO-WALLE K: Generalising the results of clinical trials to actual practice: The example of clopidogrel therapy for the prevention of vascular events. Am.! Med. (1999) 107:568–572.
   PubMed Web of Science ®Google Scholar
• LIEW D, MCNEIL JJ, PEETERS A, LIM SS, VOS T: Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Med. Aust. (2002) 177:364–367.
   PubMedGoogle Scholar
• •A basic introduction for the clinician in economic modelling and its limitations.
   Google Scholar
• http://www.who.int/whr/2002/en WORLD HEALTH REPORT: Reducing risks, promoting healthy life. World Health Organization, Geneva (2002).
   Google Scholar
• http://ww2.heartandstroke.ca/Page.asp?PageI D=1613 &ContentID=10317 &ContentTyp eID=1HEART AND STROKE FOUNDATION OF CANADA: Heart disease information — incidence of cardiovascular diseases.
   Google Scholar
• http://www.aihw.gov.au/publications/index.cf m?type=detail&id=7865AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE: Epidemic of coronary heart disease and its treatment in Australia. Cardiovascular Disease Series No. 20.
   Google Scholar